TRIB1 degrader
Acute myeloid leukemia
DiscoveryActive
Key Facts
About FIMECS
Japanese biotech developing targeted protein degradation drugs for undruggable oncology targets using its proprietary RaPPIDS™ platform.
View full company profileTherapeutic Areas
Other Acute myeloid leukemia Drugs
| Drug | Company | Phase |
|---|---|---|
| AFM28 | Affimed | Phase 1/2 |
| AML (N-Act) AI | Biostate AI | Development |
| Navtemadlin (KRT-232) | Kartos Therapeutics | Phase 1/Phase 2 |
| QL325 | QLSF Biotherapeutics | Phase 1 |
| NPM1 Testing in AML | Diatech Pharmacogenetics | Commercial |
| Joint Development for AML | Ordaos Bio | Pre-clinical |
| DFP Oncology Program | Delta-Fly Pharma | Preclinical |
| NG-202 | Nanogen Pharmaceutical Biotechnology | Preclinical |
| LBS-007 | Lin BioScience | Phase 1/2 |
| RG6356 (RO7434656) | Chugai Pharmaceutical | Phase III |
| AL8326 | Shanghai Allist Pharmaceuticals | Phase II |
| GT1709 | Kintor Pharma | Phase 1 |